Cite
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
MLA
Beppu, Toru, et al. “Liver Resectability of Advanced Liver-Limited Colorectal Liver Metastases Following MFOLFOX6 with Bevacizumab (KSCC0802 Study).” Anticancer Research, vol. 34, no. 11, Nov. 2014, pp. 6655–62. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25368271&authtype=sso&custid=ns315887.
APA
Beppu, T., Emi, Y., Tokunaga, S., Oki, E., Shirabe, K., Ueno, S., Kuramoto, M., Kabashima, A., Takahashi, I., Samura, H., Eguchi, S., Akagi, Y., Natsugoe, S., Ogata, Y., Kakeji, Y., Baba, H., & Maehara, Y. (2014). Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Research, 34(11), 6655–6662.
Chicago
Beppu, Toru, Yasunori Emi, Shoji Tokunaga, Eiji Oki, Ken Shirabe, Shinichi Ueno, Masafumi Kuramoto, et al. 2014. “Liver Resectability of Advanced Liver-Limited Colorectal Liver Metastases Following MFOLFOX6 with Bevacizumab (KSCC0802 Study).” Anticancer Research 34 (11): 6655–62. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25368271&authtype=sso&custid=ns315887.